Use of prostaglandin E1 (lipo-PGE1) to treat Raynaud's phenomenon associated with connective tissue disease: thermographic and subjective assessment

J Pharm Pharmacol. 1992 May;44(5):442-4. doi: 10.1111/j.2042-7158.1992.tb03641.x.

Abstract

Four patients with connective tissue disease who had been suffering from severe Raynaud's phenomenon were treated with an intravenous infusion of prostaglandin E1 (PGE1) and its effectiveness was assessed by thermography and a questionnaire approach. PGE1 in a lipid microsphere formulation (lipo-PGE1) produced a significantly greater increase in lesional skin temperature compared with treatment with PGE1 clathrated in alpha-cyclodextrin 12 months previously in the same group of patients. These results were supported by the subjective assessment obtained from the patients by questionnaire.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Alprostadil / adverse effects
  • Alprostadil / therapeutic use*
  • Connective Tissue Diseases / complications*
  • Connective Tissue Diseases / physiopathology
  • Female
  • Humans
  • Lupus Erythematosus, Systemic / complications
  • Male
  • Microspheres
  • Pain / drug therapy
  • Pain / psychology
  • Raynaud Disease / complications
  • Raynaud Disease / drug therapy*
  • Raynaud Disease / physiopathology
  • Skin Pigmentation
  • Skin Temperature / drug effects
  • Surveys and Questionnaires

Substances

  • Alprostadil